For the quarter ending 2025-12-31, VIVS had -$2,389K decrease in cash & cash equivalents over the period. -$2,271K in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | -2,691 | -2,545 | -2,843 |
| Interest accretion on escrow receivable | 3 | 4 | 4 |
| Accretion on investments | 0 | 0 | 0 |
| Write-downs of inventory | 0 | 0 | - |
| Depreciation and amortization | 52 | 59 | 61 |
| Stock-based compensation | 67 | 72 | 78 |
| Non-cash lease expense | 116 | 114 | 112 |
| Accounts receivable | 1 | 0 | 2 |
| Inventory | 0 | 0 | 0 |
| Prepaid expenses and other assets | -174 | -97 | -248 |
| Accounts payable | 91 | -93 | -971 |
| Accrued expenses | 47 | 44 | -499 |
| Operating lease liabiliy | -123 | -122 | -120 |
| Net cash used in operating activities | -2,271 | -2,378 | -3,940 |
| Purchases of fixed assets | 0 | 0 | - |
| Purchases of investments | 0 | 0 | 0 |
| Maturities of investments | 0 | 0 | 0 |
| Net cash provided by investing activities | 0 | 0 | 0 |
| Proceeds from issuance of common stock, net | 0 | 0 | 1,811 |
| Repayment of insurance premium financing liability | 118 | 0 | 128 |
| Net cash provided by financing activities | -118 | 0 | 1,683 |
| Net decrease in cash, cash equivalents, and restricted cash | -2,389 | -2,378 | -2,257 |
| Cash and cash equivalents at beginning of period | 6,820 | 11,455 | - |
| Cash and cash equivalents at end of period | 4,431 | 6,820 | - |
VivoSim Labs, INC. (VIVS)
VivoSim Labs, INC. (VIVS)